Investigational Drug Details
| Drug ID: | D184 |
| Drug Name: | INT-767 |
| Synonyms: | -- |
| Type: | Chemical drug |
| DrugBank ID: | -- |
| DrugBank Description: | -- |
| PubChem ID: | 23712772 |
| CasNo: | 1000403-03-1 |
| Repositioning for NAFLD: | No |
| SMILES: | O[C@H]1[C@@H]2[C@@H]([C@@]3([C@H]([C@H]1CC)C[C@@H](CC3)O)C)CC[C@]1([C@H]2CC[C@@H]1[C@@H](CCOS(=O)(=O)O)C)C.[Na] |
| Structure: |
|
| InChiKey: | DQIGKAIZUNNJGO-PMWRKVJASA-N |
| Molecular Weight: | 496.686 |
| DrugBank Targets: | -- |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | FXR agonist; TGR5 agonist |
| Therapeutic Category: | Enhance lipid metabolism |
| Clinical Trial Progress: | -- |
| Latest Progress: | Under investigation |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S02 | Enhance lipid metabolism | triglyceride-lowering; lipid tolerance; lipid metabolism | 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) inhibitor; Decreases intestinal cholesterol absorption; FXR agonist; ACC inhibitor; FAS inhibitor; DGAT2 inhibitor; SCD-1 inhibitor | Atorvastatin; Ezetimibe; Obeticholic Acid; GS-9674; GS-0976; TVB-2640; IONIS-DGAT2rx; Aramchol; | Details |
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A08711 | 32015483 | Sci Rep | Obeticholic acid and INT-767 modulate collagen deposition in a NASH in vitro model. | Details |
| A09074 | 31883514 | BMC Gastroenterol | Validity of biopsy-based drug effects in a diet-induced obese mouse model of biopsy-confirmed NASH. | Details |
| A13307 | 30038487 | Drug Des Devel Ther | Farnesoid X receptor agonist INT-767 attenuates liver steatosis and inflammation in rat model of nonalcoholic steatohepatitis. | Details |
| A13504 | 29945982 | J Endocrinol | INT-767 prevents NASH and promotes visceral fat brown adipogenesis and mitochondrial function. | Details |
| A14512 | 29375205 | World J Gastroenterol | INT-767 improves histopathological features in a diet-induced ob/ob mouse model of biopsy-confirmed non-alcoholic steatohepatitis. | Details |
| A14541 | 29361497 | Mol Metab | Reversal of metabolic disorders by pharmacological activation of bile acid receptors TGR5 and FXR. | Details |
| A16267 | 28478385 | J Biol Chem | Farnesoid X receptor induces Takeda G-protein receptor 5 cross-talk to regulate bile acid synthesis and hepatic metabolism. | Details |
| A23805 | 23460643 | J Biol Chem | Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease. | Details |
| A31513 | 30411084 | Hepatol Commun | FXR and TGR5 Agonists Ameliorate Liver Injury, Steatosis, and Inflammation After Binge or Prolonged Alcohol Feeding in Mice. | Details |